The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review

The present systematic review summarizes current evidence regarding the mechanisms of action, the efficacy, and the adverse effects of tyrosine kinase inhibitors (TKIs) in ovarian cancer patients. Phase II and III clinical trials were sought in the PubMed database and in the Clinical Trials.gov registry through September 30, 2015. Seventy-five clinical trials regarding TKIs targeting mainly vascular endothelial growth factor receptor, epidermal growth factor receptor, platelet-derived growth factor receptor, and sarcoma tyrosine kinase (Src) were yielded. The most promising results were noted with cediranib, nintedanib, and pazopanib. However, drawing universal conclusions about the potential integration of TKIs in ovarian cancer therapy remains elusive. Furthermore, emerging challenges and directions for the future research are critically discussed

The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review

<p>The present systematic review summarizes current evidence regarding the mechanisms of action, the efficacy, and the adverse effects of tyrosine kinase inhibitors (TKIs) in ovarian cancer patients. Phase II and III clinical trials were sought in the PubMed database and in the Clinical Trials.gov registry through September 30, 2015. Seventy-five clinical trials regarding TKIs targeting mainly vascular endothelial growth factor receptor, epidermal growth factor receptor, platelet-derived growth factor receptor, and sarcoma tyrosine kinase (Src) were yielded. The most promising results were noted with cediranib, nintedanib, and pazopanib. However, drawing universal conclusions about the potential integration of TKIs in ovarian cancer therapy remains elusive. Furthermore, emerging challenges and directions for the future research are critically discussed.</p

Management and Outcomes in Metaplastic Breast Cancer

Metaplastic breast cancer (MBC) constitutes a rare clinical entity with special clinicopathologic, immunohistochemical, and molecular features. Resistance to systemic therapies, whether chemotherapy or hormonal therapy, is among its main characteristics, which in turn explains the poor prognosis and renders its management a challenge. Thus, the scope of the present review is to discuss the current therapeutic strategies for MBC in clinical practice and the corresponding outcomes and to suggest possible directions for future research. Potential novel targeted therapies could provide a hope for better outcomes but limited data are available owing to the rarity of MBC. As knowledge accumulates on the pathogenesis and genetic characteristics of MBC, emphasis should be given to the implementation of more targeted treatments, which will allow more efficient and individualized management of the disease. (C) 2016 Elsevier Inc. All rights reserved

Consumption of fruits, vegetables, and risk of hematological malignancies: a systematic review and meta-analysis of prospective studies

We examined the association between fruit/vegetable consumption and the risk of hematological malignancies in cohort studies (end of search: August 31, 2016). Total fruit consumption was not associated with the risk of non-Hodgkin lymphoma (NHL) (RR = 1.03, 95% CI: 0.92–1.16, I2 = 12.1%, n = 7), acute myeloid leukemia (RR = 1.23, 95% CI: 0.94–1.61, I2 = 0%, n = 3), multiple myeloma (MM; RR = 1.05, 95% CI: 0.72–1.55, I2 = 60.0%, n = 4), and Hodgkin lymphoma. However, citrus fruit consumption was associated with reduced NHL risk (RR = 0.85, 95% CI: 0.73–1.00, p =.044, I2 = 0%, n = 6). Vegetable intake was marginally associated with reduced NHL risk (RR = 0.89, 95% CI: 0.79–1.00, p =.056, I2 = 16.2%, n = 7), but not with acute myeloid leukemia, multiple myeloma, and Hodgkin lymphoma risk. Nevertheless, NHL risk was inversely associated with cruciferous vegetable consumption (RR = 0.84, 95% CI: 0.71–1.00, p =.047, I2 = 0%, n = 3). Notably, combined fruit/vegetable consumption was associated with decreased NHL risk (RR = 0.79, 95% CI: 0.65–0.96, I2 = 11.2%, n = 3). This meta-analysis reveals possible protective effects; however, confounding and reporting bias could have affected the results. © 2017 Informa UK Limited, trading as Taylor &amp; Francis Group

Alcohol consumption and risk of hematological malignancies: a meta-analysis of prospective studies

Current convincing evidence suggests that alcohol intake increases the risk of several carcinomas, which might subsequently lead to a recommendation toward limiting alcohol consumption. However, there are accumulating data worth meta-analyzing that show a different effect on the risk of hematological malignancies. Eligible cohort studies were sought in PubMed database up to August 31, 2016. Separate analyses were performed by subtype of hematological malignancy (non-Hodgkin lymphoma [NHL] and subtypes, Hodgkin lymphoma [HL], leukemia and subtypes), time status (ever, current, former), level of consumption (light, moderate, heavy), alcoholic beverage (total alcohol, beer, liquor, wine) and gender. Moderate and heavy alcohol consumption were significantly associated with reduced risk of NHL (relative risk [RR] = 0.85, 95% confidence interval [CI]: 0.80–0.90 and RR = 0.73, 95%CI: 0.60–0.89, respectively); a protective trend was also shown for light alcohol intake (RR = 0.93, 95%CI: 0.87–1.00). Specifically, beer consumption was associated with reduced NHL risk (RR = 0.88, 95%CI: 0.81–0.95). However, the association regarding other alcoholic beverages seemed null. The beneficial effects of alcohol mainly pertained to Diffuse Large B-Cell Lymphoma (DLBCL) (RR = 0.83, 95%CI: 0.77–0.89) and Follicular Lymphoma (FL) (RR = 0.85, 95%CI: 0.78–0.93). There was also no association between alcohol consumption and risk of HL or leukemias. In contrast to most solid malignancies, alcohol seems to confer a protective effect on NHL risk, especially on DLBCL and FL subtypes, with beer being notably beneficial. © 2018 UIC

Meat, fish, dairy products and risk of hematological malignancies in adults--a systematic review and meta-analysis of prospective studies

This systematic review and meta-analysis of cohort studies examine the association of meat, fish, and dairy product consumption with the risk of hematological neoplasms in adults. Thirteen studies encompassing 1,480,986 participants and 10,442 incident cases were included. Red or processed meat consumption was not associated with the risk of leukemia, acute myeloid leukemia, non-Hodgkin lymphoma (NHL) and small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL/SLL). Poultry consumption did not seem to affect the risk of leukemia, NHL, CLL/SLL, and multiple myeloma (MM). Fish consumption was not associated with leukemia, NHL, CLL/SLL, and MM risk. Interestingly though, fish consumption was positively associated with myeloid leukemia risk (pooled RR = 1.74, 95% CI: 1.22–2.47, random effects, highest vs. lowest category). Milk and dairy product consumption was not associated with NHL and leukemia risk. In conclusion, methodologically strict prospective studies are mandatory, in order to extract reliable conclusions concerning the role of these dietary factors in hematological malignancies. © 2019, © 2019 Informa UK Limited, trading as Taylor &amp; Francis Group

Anthropometric characteristics, physical activity and risk of hematological malignancies: a systematic review and meta-analysis of cohort studies

Overweight/obesity, adult attained height and physical activity are possible risk factors for hematological malignancies. This meta-analysis aims to evaluate the associations between these factors and hematological cancer risk in adults. Eligible cohort studies were sought in PubMed up to May 31, 2016; overall, 44 studies were included in the present analyses. Pooled relative risk estimates were calculated using random-effects models; separate analyses were conducted for non-Hodgkin lymphoma (NHL) and subtypes (diffuse large B-cell lymphoma, DLBCL; follicular cell lymphoma; small lymphocytic lymphoma/chronic lymphocytic leukemia, SLL/CLL), Hodgkin lymphoma (HL), multiple myeloma (MM), leukemia and subtypes (acute lymphoblastic leukemia, acute myeloid leukemia, AML). Obesity was associated with increased risk of NHL, HL, MM, leukemia overall and AML in both sexes, as well as with higher DLBCL risk in women; the dose–response meta-regression analysis confirmed these associations. Less pronounced effects were observed regarding overweight, as it was associated with increased MM risk in both sexes, NHL risk in males, DLBCL and overall leukemia risk in females. Taller men presented with significantly higher risk of NHL and taller women were affected by higher risk of NHL, DLBCL, FL, CLL/SLL, MM, leukemia and AML. On the other hand, physical activity and abdominal fatness were not associated with the risk of hematological malignancies. In conclusion, this meta-analysis highlights the pivotal role of anthropometric measures in shaping the risk of hematological malignancies in adults. Additional, well-designed studies stemming from all the continents are needed for the further substantiation and generalization of the results. © 2019 UIC